Responses
Poster Presentations
SLE, Sjögren's and APS - treatment
SAT0222 BIIB059, a monoclonal antibody targeting BDCA2, shows evidence of biological activity and early clinical proof of concept in subjects with active cutaneous le
Compose a Response to This Article
Other responses
No responses have been published for this article.